On June 22, 2026 Hamlet BioPharma AB (publ) reported the signing of a clinical trial agreement with the University of Iowa, one of the leading U.S. centers for bladder cancer research and therapy. The new study advances the clinical development of Alpha1H, a human breast milk derived treatment for bladder cancer, to include Carcinoma In Situ (CIS); a severe surface-spreading and therapy-resistant form of bladder cancer where patients may need to remove their bladders to avoid systemic disease.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Professor O’Donnell, a key opinion leader and driver of the international bladder cancer therapy field, has identified a significant unmet medical need among patients with CIS and initiated discussions with Hamlet BioPharma and scientists at Lund University, regarding this clinical expansion of the Alpha1H drug development program. This collaboration follows an extensive scientific and clinical evaluation of Alpha1H by the University of Iowa, including review of published clinical data and the mechanism of action described in peer-reviewed publications.
Bladder cancer is one of the most common urological malignancies worldwide. A substantial proportion of patients experience recurrence following treatment, creating a significant need for new therapies that can reduce recurrence rates and preserve bladder function. The clinical study is planned to be conducted under Hamlet BioPharma’s existing Investigational New Drug (IND) application for Alpha1H in the United States through submission of a new clinical protocol amendment to the U.S. Food and Drug Administration (FDA).
"The signing of this agreement establishes a collaboration with the University of Iowa group, led by Professor O’Donnell, who are pioneers in the field and have defined multiple novel therapies in bladder cancer. Expanding the clinical indications to include CIS allows us to evaluate Alpha1H in a patient population with severe and resistant disease and a substantial unmet medical need," says Catharina Svanborg, Professor at Lund University and Chairman of the Board of Hamlet BioPharma.
"Despite advances in bladder cancer treatment, high recurrence rates remain a major challenge. Many patients with CIS have exhausted all available treatments, without a cure, and are faced with the prospect of bladder removal. Based on our evaluation of Alpha1H and the clinical results generated to date, we believe the Alpha1H treatment warrants further investigation in this patient group. We look forward to working with Hamlet BioPharma and the scientists at Lund University to explore the potential of Alpha1H in patients with treatment resistant CIS," says Michael O’Donnell, Professor and Director of Urologic Oncology at the University of Iowa.
(Press release, HAMLET Pharma, JUN 22, 2026, View Source [SID1234668884])